Core Viewpoint - The controlling shareholder of Xuantai Pharmaceutical, Shanghai Lianhe Investment Co., Ltd., has voluntarily committed not to reduce its shareholding in the company for 24 months starting from August 25, 2025, to enhance investor confidence and maintain market stability [1][2]. Group 1: Shareholder Commitment - The commitment from the controlling shareholder comes at a critical time when the company's original shareholders' restricted shares are about to be unlocked, alleviating market concerns about large-scale share reductions [2]. - On August 25, 2023, a total of 311 million shares will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [2]. - The actual reducible shares will be significantly reduced to 7.8 million shares, effectively easing potential liquidity pressure from the concentrated unlocking [2]. Group 2: Business Strengths - Xuantai Pharmaceutical's long-term outlook is supported by its robust core strategic business and the competitive barriers of its high-end formulation technology [3]. - The company focuses on high-end generic drugs and has developed a leading drug chemical formulation platform in China, with a strong emphasis on R&D and technological innovation [3]. - The product portfolio includes 16 approved products by the end of 2024, with several being first generics in both domestic and international markets [3]. Group 3: CRO/CMO Performance - In the CRO/CMO sector, Xuantai Pharmaceutical has successfully assisted in the approval and commercialization of multiple innovative drugs, with over 100 projects completed for global clients [4]. - The company has established partnerships with several well-known pharmaceutical companies, enhancing its market presence and service capabilities [4]. Group 4: Shareholder Returns - Xuantai Pharmaceutical has consistently prioritized shareholder returns, implementing a stable and continuous dividend policy, with a total cash dividend of 74.36 million yuan since its listing in 2022 [5][6]. - The company completed a share buyback in February 2025, repurchasing 4.3361 million shares, which represents 0.96% of the total share capital, further demonstrating its commitment to enhancing shareholder value [6]. - The controlling shareholder's commitment not to reduce holdings is seen as a strong vote of confidence in the company's long-term strategy and management team, reinforcing the company's positive image in the capital market [6].

控股股东的长期看好不仅源于宣泰医药核心战略业务的蓬勃发展和广阔的行业前景，同时亦来自公司高 端制剂技术的核心竞争力壁垒。在仿制药领域，宣泰医药依托"难溶药物增溶技术平台"、"缓控释药物 制剂研发平台"和"固定剂量药物复方制剂研发平台"三大技术平台，持续投入研发高技术壁垒的产品。 截至2024年底，宣泰医药已获批上市产品达到16款，其中多款国内外首仿产品。除中国市场外，公司产 品已远销美国、澳大利亚、新加坡、以色列、海湾国家和加拿大等多个国家或地区。今年以来，公司产 品恩杂鲁胺片、达格列净二甲双胍缓释片先后获得美国FDA暂时批准，为未来进入美国市场打下坚实基 础。 在CRO/CMO领域，宣泰医药表现同样亮眼。今年7月，宣泰医药助力亚盛医药利生妥 （利沙托克拉 片）、征祥医药济可舒（玛硒洛沙韦）获NMPA批准上市，并由宣泰医药全资子公司江苏宣泰药业有限 公司提供后续CMO服务。截至目前，宣泰医药顺利推进了累计超过100个创新药的制剂开发，其中8款 新药产品已获批上市并由宣泰药业承接后续商业化生产CMO服务。客户涵盖歌礼制药、亚盛医药、再 鼎医药、艾力斯、益方生物等多家上市公司，以及辉瑞普强、海和药物、璎黎药业等国 ...

Pharmaceutical Industry - Several companies in the innovative drug sector have shown significant stock price increases, with notable performances including Ruizhi Pharmaceutical up by 19.98% and Longxin Pharmaceutical up by 10.04% [2][3] - The overall sentiment in the innovative drug investment environment is improving, with a resurgence in financing activities for sectors like peptides and ADCs, which is expected to boost the CXO industry [11] Solid-State Battery - Solid-state batteries are projected to begin vehicle testing by 2027 and achieve mass production by 2030, leading to stock price increases for companies like Dexin Technology, which rose by 10.01% [4] - Other companies involved in solid-state battery technology, such as Hailan Pharmaceutical and Yinglian Co., also experienced significant stock gains [6] Digital Currency - The listing of Circle, the first stablecoin company, saw a 29.4% increase in stock price, influencing related stocks like Jinshi Technology, which rose by 9.97% [7] Robotics - The upcoming World Humanoid Robot Games is expected to showcase advancements in robotics, positively impacting stocks like Dongbei Group, which increased by 9.99% [8][10] Agriculture and Pesticides - ST Hongyang announced a price increase for its chlorantraniliprole product to 300,000 yuan per ton, a significant rise from last year's low of 210,000 yuan, benefiting companies like Lianhua Technology [13][14] Rare Earth Permanent Magnet - The Chinese government has implemented export controls on rare earths, which aligns with international practices, leading to stock price increases for companies like Beikong Technology [15][16] Sports Industry - The Hong Kong Legislative Council is set to discuss regulations for basketball betting, which may positively affect stocks in the sports sector, such as Gongchuang Turf [19] Military Industry - Indonesia's consideration of China's J-10 fighter jet, based on its performance in conflicts, is influencing military-related stocks like Lijun Co. [20] Financial Sector - Recent approvals for changes in actual controllers of several securities firms, including Changcheng Guorui Securities, have led to stock price increases in the financial sector [22] Food and Beverage - Morgan Stanley's report indicates improving sentiment among international investors towards Chinese stocks, particularly in the "new consumption" and technology sectors, benefiting companies like XD Jiao Da Ang [23] Dental Medical - A forecast by Frost & Sullivan predicts a significant increase in the demand for dental implants in China, with a compound annual growth rate of 30.97%, positively impacting stocks like Haochen Medical [26][27] Automotive Industry - China's electric vehicle exports have grown by 19% in the first five months of the year, leading to stock price increases for companies like Jianghuai Automobile [30][32]

Macro Dynamics - The People's Bank of China and the State Administration of Foreign Exchange have drafted a notice to improve and unify the management of cross-border funds for domestic companies listed overseas, enhancing the convenience of cross-border financing for domestic enterprises [1] - The notice allows for the return of funds raised from overseas listings in either foreign currency or RMB, with flexibility in foreign exchange risk management [1] Foreign Investment - In the first four months of 2025, China established 18,832 new foreign-invested enterprises, a year-on-year increase of 12.1%, while the actual use of foreign capital amounted to 320.78 billion RMB, a decrease of 10.9% [2] - The manufacturing sector attracted 84.06 billion RMB, and the service sector attracted 231.25 billion RMB in foreign investment [2] - High-tech industries saw a significant increase in foreign investment, with e-commerce services up 137%, aerospace manufacturing up 86.2%, and pharmaceutical manufacturing up 57.8% [2] Financial Institutions - Nomura Holdings reported that the total compensation for its seven executives reached 4.6 billion JPY (approximately 320 million USD), marking a 3% increase from the previous year and the highest level in over a decade [6] - The company achieved a record profit of 340.7 billion JPY, benefiting from a rebound in global securities trading and improved cost control [6] Company Dynamics - Sinopec has invested in CATL as a cornerstone investor during its IPO on the Hong Kong Stock Exchange, aiming to promote the construction of new battery swap station infrastructure [11] - Jinhua Co., Ltd.'s chairman is under investigation for alleged violations related to stock disclosure, but this will not affect the company's daily operations [12] - Spring Airlines plans to launch a new route from Shanghai to Hanoi, Vietnam, starting July 2, 2025, with plans to expand its Southeast Asia route network based on market demand [13] - Apple has announced a trade-in program for new iPhones, offering additional discounts ranging from 50 to 400 RMB for customers trading in older models [14]